Omeros Corp.

Omeros Corp. is a clinical‑stage biotech focused on complement‑pathway therapeutics for rare immunologic diseases. Its lead candidate, Narsoplimab (OMS721), is in Phase III for TA‑TMA, while additional MASP‑2/3 programs target unmet needs.

Headquarters: United States (USA)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Professional Services
Industry: Biotechnology Research

Employees: 202
HQ: Seattle

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
OMER	Omeros Corp. Cap: 0.9B	EQUITY	NGM	USD	US6821431029	Active	📈